Chelexa BioSciences, inc.
Chelexa is developing and commercializing unique and disruptive topical drug products that prevent serious infections and save lives.
Chelexa develops and commercializes unique topically applied drug products that prevent serious infections in surgical sites and chronic wounds. Our technology targets over 10 million US patients and a $10 billion market. Our first product, BioLexa, combines 2 FDA approved drugs in a proprietary formulation to prevent bacterial proliferation, colonization and biofilm related infections. BioLexa is planned to launch in 2016.